Hologic (HOLX) Up on Preliminary Q1 Organic Sales Growth
Hologic's (HOLX) Diagnostics division's preliminary numbers show a strong rebound in the base business.
Hologic Inc. HOLX announced lackluster preliminary revenues for first-quarter fiscal 2022 (ended Dec 25, 2021) on Jan 9. The company estimates a year-over-year decline in total revenues. However ex-covid revenue growth was satisfactory, indicating a strong base business rebound. The preliminary total revenues exceeded the Zacks Consensus Estimate as well as the company’s estimates. The stock rose 4.5% the following day to close at $73.45.
The company is slated to release its full financial results for the period on Feb 2.
Prelim Q1 at a Glance
Per the preliminary announcement, total revenues for the fiscal first quarter are expected to be approximately $1,471.1 million, implying a projected 8.6% decline year over year (down 8.2% at constant exchange rate or CER). However, this preliminary figure exceeds the Zacks Consensus Estimate of $1.12 billion by a wide margin. The preliminary expectation also remains ahead of the company’s guidance range of $1,100 to $1,150 million, provided on Nov 1, 2021.
Image Source: Zacks Investment Research
Hologic’s Diagnostics division’s preliminary numbers show a strong rebound in base business while meeting heavy demand for COVID testing. The Breast and Skeletal Health and Surgical businesses also showed strength, with each growing over 8% as per the prelim announcements. Overall, the company projects organic growth excluding COVID benefits to be 9.0% at CER in the fiscal first quarter compared with its 5% to 7% long-term growth target.
On a segmental basis, while Diagnostics revenues are likely to fall 15.2% at CER, Organic Diagnostics revenues, excluding COVID, are likely to rise 10% at CER.
GYN Surgical (7.7%) is estimated to grow 8.2% at CER on a year-over-year basis. Breast Health (20.7%) revenues are likely to rise 8.4% at CER. Skeletal Health (1.5%) is anticipated to rise 9.7% at CER.
Preliminary organic revenues, excluding COVID, are expected at $840.9 million, implying 9% year-over-year growth at CER.
The company expects fiscal first-quarter adjusted earnings per share (EPS) to be $1.15-$1.25, with a projected decline of 59.8-56.3% year over year. The current Zacks Consensus Estimate is pegged at $1.17.
In Diagnostics, in October, the company’s Aptima SARS-CoV-2/Flu Assay was made available for the simultaneous detection and differentiation of three respiratory viruses that can present overlapping clinical symptoms. The three viruses – SARS-CoV-2, influenza A and influenza B – typically cause similar symptoms including fever, cough, headache and fatigue. With the potential for seasonal flu in addition to the ongoing COVID-19 pandemic, physicians are expected to test patients presenting with these shared symptoms for all three viruses. This while opening up the scope for testing is likely to have contributed significantly to the quarter’s diagnostic testing revenues.
Share Price Movement
Hologic has outperformed its industry over the past six months. The stock has gained 5.3% against a 2.5% decline of its industry.
Zacks Rank & Other Stocks to Consider
Currently, Hologic carries a Zacks Rank #2 (Buy).
AMN Healthcare, carrying a Zacks Rank #1 (Strong Buy), has a long-term earnings growth rate of 16.2%. The company’s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 19.5%, on average.
AMN Healthcare has outperformed its industry over the past year. AMN has gained 48.3% against the 57.3% industry decline.
Apollo Endosurgery, carrying a Zacks Rank #2 (Buy), has a long-term earnings growth rate of 7%. The company‘s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 25.6%, on average. You can see the complete list of today’s Zacks #1 Rank stocks here.
Apollo Endosurgery has outperformed its industry in the past year. APEN has gained 103.3% versus the industry’s 1% fall.
Patterson Companies, sporting a Zacks Rank #2, has a long-term earnings growth rate of 9.9%. The company surpassed earnings estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.7%.
Patterson Companies has underperformed its industry over the past year. PDCO has declined 11.1% versus the industry’s 4.9% rise.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hologic, Inc. (HOLX): Free Stock Analysis Report
Patterson Companies, Inc. (PDCO): Free Stock Analysis Report
AMN Healthcare Services Inc (AMN): Free Stock Analysis Report
Apollo Endosurgery, Inc. (APEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research